Fanning the flames: Inflammation in cardiovascular diseases

Cardiovascular Research

Volumn 107, Issue 3, 2015, Pages 307-309

  Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 10; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; HEART INFARCTION; HOST RESISTANCE; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; LEUKOCYTE; MACROPHAGE; MAST CELL; MONOCYTE; MONONUCLEAR PHAGOCYTE; NEUTROPHIL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; VASCULITIS; IMMUNOLOGY; INFLAMMATION; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; LEUKOCYTES;

EID: 84942080373     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv188     Document Type: Review

References (10)

1. Libby P. History of discovery: inflammation in atherosclerosis. Arterioscler Thromb J Vasc Biol 2012;32:2045-2051.
2. Shaw G. The Doctor's Dilemma. Baltimore, MD: Penguin Books, Inc.; 1911.
3. Libby P, Nahrendorf M, Swirski FK. Monocyte heterogeneity in cardiovascular disease. Semin Immunopathol 2013;35:553-562.
4. Libby P, Hansson GK, Lichtman AH. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013;38:1092-1104.
5. Oh SF, Dona M, Fredman G, Krishnamoorthy S, Irimia D, Serhan CN. Resolvin E2 formation and impact in inflammation resolution. J Immunol 2012;188: 4527-4534.
6. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014;114:1867-1879.
7. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-410.
8. Everett BM, Pradhan AD, Solomon DH, Paynter N, MacFadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AAK, Glynn RJ, Ridker PM. Rationale and design of the cardiovascular inflammation reduction trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207.
9. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162: 597-605.
10. O'donoghue ML, Glaser R, Aylward PE, Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG, Theroux P, Sabatine MS, Morrow DA. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J 2015;169: 622-630 e6.